Recently, FDA approved tildrakizumab-asmn for specific treatments of plaque psoriasis- moderate to severe, especially for the candidates intended for systemic or phototherapy. Tildrakizumab-asmn belongs to the category of monoclonal antibodies and is an interleukin-23 antagonist. Abounding as a solution for subcutaneous shots, the endorsed dosage of Ilumya is 100 mg at weeks 0, 4 and thereafter every twelve weeks.
This humanized IgG1/k monoclonal antibody binds to the IL-23 (a cytokine involved in inflammatory and immune response) and therefore inhibits the interaction with IL-23 receptor. As per the data received from the Pivotal, Phase III, two multicentre, randomized, double-blind, placebo-controlled trials of (resSURFACE) clinical development program, about 616 candidates were treated with tildrakizumab-asmn whereas 310 of the patients were treated with placebo. The studies were…
